Status:
UNKNOWN
The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of...
Eligibility Criteria
Inclusion
- diagnosis of multiple myeloma
- availability of abnormal plasmocytes
Exclusion
- \- none
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2024
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05331313
Start Date
December 1 2022
End Date
August 31 2024
Last Update
April 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Pierre-Bénite, France, 69495